JP2017528485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528485A5 JP2017528485A5 JP2017514665A JP2017514665A JP2017528485A5 JP 2017528485 A5 JP2017528485 A5 JP 2017528485A5 JP 2017514665 A JP2017514665 A JP 2017514665A JP 2017514665 A JP2017514665 A JP 2017514665A JP 2017528485 A5 JP2017528485 A5 JP 2017528485A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- cycloalkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052731 fluorine Inorganic materials 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- -1 2-oxo-dihydrofuranyl Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185224 | 2014-09-17 | ||
| EP14185224.4 | 2014-09-17 | ||
| PCT/EP2015/070741 WO2016041845A1 (en) | 2014-09-17 | 2015-09-10 | Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528485A JP2017528485A (ja) | 2017-09-28 |
| JP2017528485A5 true JP2017528485A5 (OSRAM) | 2018-10-18 |
| JP6559228B2 JP6559228B2 (ja) | 2019-08-14 |
Family
ID=51564524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514665A Active JP6559228B2 (ja) | 2014-09-17 | 2015-09-10 | 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9340510B2 (OSRAM) |
| EP (1) | EP3194367B1 (OSRAM) |
| JP (1) | JP6559228B2 (OSRAM) |
| WO (1) | WO2016041845A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201912168TA (en) | 2017-07-11 | 2020-01-30 | Boehringer Ingelheim Int | Novel substituted xanthine derivatives |
| US11459324B2 (en) * | 2018-03-14 | 2022-10-04 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
| TWI785660B (zh) * | 2020-07-02 | 2022-12-01 | 美商輝瑞大藥廠 | 嘧啶基-3,8-二氮雜雙環[3.2.1]辛烷基甲酮衍生物及其鹽之製備 |
| US20250041279A1 (en) | 2021-11-19 | 2025-02-06 | Shionogi & Co., Ltd. | Therapeutic medicine for heart disease or skeletal muscle disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1029851B1 (en) | 1997-10-14 | 2005-04-20 | Mitsubishi Pharma Corporation | Piperazine compounds and medicinal use thereof |
| BR0010308A (pt) * | 1999-05-06 | 2002-01-08 | Neurogen Corp | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa e para alterar a atividade da transdução de sinal dos receptores de gabaa, e, composição farmacêutica embalada |
| JP2004143134A (ja) * | 2002-02-13 | 2004-05-20 | Takeda Chem Ind Ltd | Ｊｎｋ阻害剤 |
| WO2006058628A2 (en) * | 2004-11-30 | 2006-06-08 | F.Hoffmann-La Roche Ag | Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| CA2724603A1 (en) * | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| WO2010127212A1 (en) * | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
| US9006450B2 (en) | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| CN102451178A (zh) | 2010-10-29 | 2012-05-16 | 中国科学院上海药物研究所 | 二氢呋喃-2-酮类化合物在制备抗糖尿病及糖脂代谢药物中的用途 |
-
2015
- 2015-09-10 WO PCT/EP2015/070741 patent/WO2016041845A1/en not_active Ceased
- 2015-09-10 EP EP15760470.3A patent/EP3194367B1/en active Active
- 2015-09-10 JP JP2017514665A patent/JP6559228B2/ja active Active
- 2015-09-16 US US14/855,668 patent/US9340510B2/en active Active